

2021 Latin America Nucleic Acid Testing (NAT) Market Assessment of 22 Countries-Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts for 100 Infectious, Genetic, Cancer, Forensic and Paternity Tests-Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

<https://marketpublishers.com/r/2151641315FBEN.html>

Date: February 2021

Pages: 1125

Price: US\$ 14,500.00 (Single User License)

ID: 2151641315FBEN

Abstracts

This new 22-country report from LeadingMarketResearch.com is available by country, market segment, section, or individual test.

The report is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during the next five years. The report is available by section, and can be customized to specific information needs and budget.

Highlights

Five-year test volume and sales forecasts

Strategic profiles of market players and start-up firms developing innovative technologies and products

Emerging technologies

Review of molecular diagnostic analyzers

Specific product and business opportunities for instrument and consumable suppliers

Rationale

The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods.

In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years.

Country Analyses

Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominican Republic, Ecuador, El Salvador, Guatemala, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Puerto Rico, Uruguay, Venezuela

Market Segmentation Analysis

Sales and market shares of key suppliers of molecular diagnostic reagent kits and components in major markets.

Five-year test volume and sales forecasts for major applications, including:

Infectious Diseases

Forensic Testing

Cancer

Paternity Testing/HLA Typing

Genetic Diseases

Others

Five-year test volume and sales projections for over 30 NAT assays.

A comprehensive analysis of the sequencing market, by country and laboratory segment, including:

Industrial

Academic

Government

Commercial

Market segmentation analysis, including review of the market dynamics, trends, structure, size, growth and suppliers in major countries.

Product/Technology Review

Comparison of leading molecular diagnostic analyzers marketed by Abbott, Beckman Coulter, BD, Bio-Rad, Gen-Probe, Roche, Tecan and other suppliers.

Extensive review of molecular diagnostic technologies, test formats, detection methodologies, trends in testing automation and over 30 target/signal amplification methods, including:

PCR

bDNA

SDA

NASBA

TMA

SSSR, and others

LCR

Universities and research centers developing new molecular diagnostic technologies and products.

Competitive Assessments

Extensive strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new technologies/products in R&D.

Companies developing and marketing molecular diagnostics products, by test and application.

Opportunities and Strategic Recommendations

Specific new product development opportunities with potentially significant market appeal during the next five years.

Design criteria for new products.

Alternative market penetration strategies.

Potential market entry barriers and risks.

Business planning issues and concerns.

Contains 1,225 pages and 148 tables

Contents

I. INTRODUCTION

II. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

- A. Instrumentation
- B. Reagent Kits and Test Systems/panels
- C. Computers, Software and Automation
- D. Auxiliary Products

III. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

IV. ALTERNATIVE MARKET PENETRATION STRATEGIES

- A. Internal Development
- B. Collaborative Arrangements
- C. University Contracts
- D. Distribution Strategies for Decentralized Testing Markets

V. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

- A. Market Maturity
- B. Cost Containment
- C. Competition
- D. Technological Edge and Limitations
- E. Patent Protection
- F. Regulatory Constraints
- G. Decentralized Testing Market Challenges

VI. MARKET AND TECHNOLOGY REVIEW

- A. DNA Sequencing
 - 1. Introduction
 - 2. Sequencing Methods
 - 3. Autoradiography
 - 4. The Human Genome Project
 - 5. Sequencing Automation
 - 6. Image Scanners

7. Fluorescent Detection
 8. Gene Profiling
 9. Gene Expression
 10. Polymorphism Screening
 11. Protein Interaction Networks
- B. DNA and RNA Probe Technologies
1. Basic Principles
 2. Probe Preparation
 3. The DNA Probe Test
 4. Test Formats
 5. Labeling Techniques
 6. Amplification Methods
- C. Detection Technologies
1. Radioactive Methods
 2. Non-Isotopic Methods
- D. Instrumentation
- Review of latest analyzers from Abbott, Beckman Coulter/Danaher, ??? Becton Dickinson, bioMerieux, Bio-Rad, Cepheid, Hologic, Qiagen, Roche, ?†?Siemens Healthineers, and others.
- E. Biochips: Genosensors, Microarrays, and Labs-on-the-Chip
- F. Pharmacogenomics
- G. Major Applications
1. Microbiology/Infectious Diseases
 - a. Overview
 - b. Major Infectious Diseases
 - AIDS: HIV/HIV-1/2/Combo, HIVAg/HIV NAT, Western Blot, HTLV-I/II
 - Adenovirus
 - Aeromonas
 - Anthrax/Bacillus Anthracis
 - Arboviruses
 - Babesiosis
 - Bacillary Epithelioid Angiomatosis (BEA) and Other Bartonella (Rochalimaea)
 - Blastocystis Hominis
 - Brucella
 - Campylobacter
 - Candida
 - Chagas Disease
 - Chancroid
 - Chlamydia

Clostridium Difficile
Coronaviruses
Coxsackieviruses
Creutzfeldt-Jakob's Disease
Cryptosporidium Parvum
Cyclospora Cayetanensis
Cytomegalovirus
Ebola Virus
E. Coli
EchoVirus
Encephalitis
Enteroviruses
Epstein-Barr Virus
Giardia Lamblia
Gonorrhea
Granuloma Inguinale
Hantavirus
Helicobacter Pylori
Hepatitis: HAV NAT, HBV NAT, HBs Ag, HCV, HCV NAT, Anti-HBc, Anti-HBs, Anti-HAV, Hepatitis Delta, HBc Ag, HBe Ag, ALT/SGPT
Herpes Simplex Virus
Human Herpes Virus-6 (HHV-6)
Influenza Viruses
Legionella
Lyme Disease
Lymphogranuloma Venereum (LGV)
Malaria
Measles (Rubeola)
Meningitis
Microsporidium
Mononucleosis
Mumps
Mycoplasma
Papillomaviruses
Parvovirus B19
Pneumonia
Polyomaviruses
Pseudomonas Aeruginosa
Rabies

Respiratory Syncytial Virus (RSV)

Rhinoviruses

Rotavirus

Rubella

Salmonellosis

Septicemia

Shigellosis

Staphylococcus Aureus

Streptococci

Syphilis

Toxoplasmosis

Trichomonas Vaginalis

Tuberculosis

Vibrio

West Nile Virus

Yersina

2. Cancer Testing

a. Overview

b. Major Cancer Types

Prostate

Lung

Colon and Rectum

Breast

Skin

Uterine

Leukemia

Oral

c. Oncogenes

The report provides review of both current and emerging oncogenes, including:

Abl/abl-bcr

AIB1

BCL-2

BRCA1

CD44

C-fos

C-myb

C-myc

CYP17

Erb-B

HPC1

N-myc

P40

P51

P53

PIK3CA

PTI-1

Ras

Reg

Sis

Src

3. Genetic Diseases

a. Overview

b. Nucleic Acid Amplification

c. Chromosome Imaging

d. Genomics Technologies

e. Proteomics Technologies

f. Current Pharmacogenomic Tests

g. Future Pharmacogenomic Testing

h. Major Diseases

Achondroplasia

Autosomal Dominant Polycystic Kidney Disease

Cancer

Cosmetogenomics

Cystic Fibrosis

Down's Syndrome

Duchenne and Becker Muscular Dystrophy

Factor V (Leiden)

Factor IX Deficiency

Fragile X Syndrome

Heart Disease

Hemochromatosis

Hemophilia

Huntington's Disease

Maternal-Fetal Incompatibility

Multiple Endocrine Neoplasia

Phenylketonuria (PKU)

Polycystic Kidney Disease (PKD)

Prenatal Screening

- Retinitis Pigmentosa
- Retinoblastoma
- Sickle Cell Anemia
- Spinal Muscular Atrophy
- Vitamin B12 Metabolism
- i. Social Issues and Concerns
- 4. Forensic Testing
 - a. Overview
 - b. Multilocus and Single Locus Probes
 - c. The FBI
 - d. DNA Profile Data Banks
 - e. Judicial Implementation
 - f. Major Crime Categories
 - g. Factors Contributing to the DNA Probe Market Expansion
 - h. Wildlife Forensics
- 5. Paternity Testing/HLA Typing
- 6. Other Applications
 - a. Disease Susceptibility Testing
 - b. Cardiovascular Diseases
 - c. Diabetes
 - d. Alzheimer's Disease
 - e. Periodontal Disease
 - f. Plasma Purification
 - g. Organ Transplantation
 - h. Water Contamination
 - i. Other
- H. Competing/Complementing Technologies
 - 1. Monoclonal Antibodies/Immunoassays
 - 2. RNA Probes
 - 3. Two-Dimensional Electrophoresis
 - 4. Flow Cytometry

VII. MOLECULAR DIAGNOSTICS MARKET

- A. Executive Summary
- B. Business Environment
- C. Market Structure
- D. Market Size, Test Volume and Sales Forecasts, Major Supplier Sales and Market Shares

VIII. COMPETITIVE ASSESSMENTS

The report provides strategic assessments of over 40 leading molecular diagnostics market players and start-up companies with innovative technologies and products, including:

Abbott, Agilent Technologies, Beckman Coulter/Danaher, Becton Dickinson, bioMerieux, Bio-Rad, Cepheid, DiaSorin, Eiken Chemical, Enzo, Fujirebio, Grifols, Hologic, Illumina, LabCorp/Sequenom, Leica Biosystems, Myriad Genetics, OrthoClinical Diagnostics, Qiagen, Quest Diagnostics, Quidel, Roche, Shimadzu, Siemens Healthineers, Sierra Molecular, Takara Bio, Tecan Group, Thermo Fisher, Wako and others.

List Of Tables

LIST OF TABLES

Major Companies Developing or Marketing AIDS Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Adenovirus Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Bartonella Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Campylobacter Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Candida Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Chlamydia Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Clostridium Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Coronavirus Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Cryptosporidium Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing CMV Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Echovirus Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Enterovirus Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing EBV Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Giardia Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Gonorrhoea Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Hantavirus Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Helicobacter Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Hepatitis Molecular Diagnostic and Other

Direct Identification Tests

Major Companies Developing or Marketing Herpes Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Influenza Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Legionella Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Lyme Disease Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Measles Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Meningitis Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Mononucleosis Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Mumps Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Mycoplasma Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Pneumonia Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing RSV Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Rotavirus Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Rubella Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Salmonella Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Septicemia Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Shigella Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Streptococci Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Syphilis Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Toxoplasmosis Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Trichomonas Molecular Diagnostic and Other Direct Identification Tests

Major Companies Developing or Marketing Tuberculosis Molecular Diagnostic and Other Direct Identification Tests

Oncogenes Potential Application in Cancer Diagnosis

Major Companies Developing or Marketing Cancer Molecular Diagnostic Tests

Major Companies Developing or Marketing Molecular Diagnostic Tests For Genetic Diseases

Germany

Molecular Diagnostics Test Volume And Sales By Major Application

Germany

Laboratories Performing DNA Sequencing By Market Segment

Germany

Molecular Diagnostics Market Potential Laboratory Universe by Market Segment

Germany

Molecular Diagnostics Test Volume By Major Application

Germany

Major Infectious Disease Test Volume by Assay

Germany

Major Infectious Disease Test Volume by Method

Germany

Molecular Diagnostics Market By Major Application

Germany

Molecular Diagnostics Market Estimated Sales And Market Shares of Major Suppliers

Germany

Major Infectious Disease Diagnostics Market by Assay

Germany

AIDS Testing Market Estimated Sales by Major Supplier

Germany

CMV Testing Market Estimated Sales by Major Supplier

Germany

EBV Testing Market Estimated Sales by Major Supplier

Germany

Gonorrhea Testing Market Estimated Sales by Major Supplier

Germany

Hepatitis Testing Market Estimated Sales by Major Supplier

Germany

Hepatitis C Testing Market Estimated Sales by Major Supplier

Germany

HIV/Hepatitis Blood Screening NAT Market Reagent Sales by Major Supplier

Germany

Herpes Testing Market Estimated Sales by Major Supplier

Germany

Influenza Testing Market Estimated Sales by Major Supplier

Germany

Meningitis Testing Market Estimated Sales by Major Supplier

Germany

Mycoplasma Testing Market Estimated Sales by Major Supplier

Germany

Pneumonia Testing Market Estimated Sales by Major Supplier

Germany

RSV Testing Market Estimated Sales by Major Supplier

Germany

Rotavirus Testing Market Estimated Sales by Major Supplier

I would like to order

Product name: 2021 Latin America Nucleic Acid Testing (NAT) Market Assessment of 22 Countries-Competitive Shares and Growth Strategies, Volume and Sales Segment Forecasts for 100 Infectious, Genetic, Cancer, Forensic and Paternity Tests-Latest Technologies and Instrumentation Pipeline, Emerging Opportunities for Suppliers

Product link: <https://marketpublishers.com/r/2151641315FBEN.html>

Price: US\$ 14,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/2151641315FBEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below
and fax the completed form to +44 20 7900 3970